Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

OMF Funds ME / CFS Treatment Trial

As someone aware of the impact of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS), you understand, as we do, that there is an urgent need to improve the clinical care for people suffering from this devastating condition.

#MayMomentum is all about ensuring that research into ME / CFS and other related chronic, complex diseases leads to results and to life-changing treatments. We hope that you will give today in honor of #GivingTuesdayNow, and show the world that there has never been a more important time to fight ME / CFS!

With a focus on treatment, OMF has invested $150,000 to study people with ME / CFS who demonstrate Preload Failure during an invasive cardiopulmonary exercise test (iCPET). I have asked Christopher W. Armstrong, PhD, Science Liaison at Open Medicine Foundation to explain why we are so excited about this latest project:

“I am deeply gratified to reveal the first of two new clinical trials focused solely on treatment options for people with ME / CFS, the Mestinon Clinical Trial for ME / CFS.

This trial is being conducted at the Brigham & Women’s Hospital by Dr. David Systrom in association with the Harvard ME / CFS Collaboration at the Harvard Affiliated Hospitals. Dr. Systrom has found that some people with ME / CFS and suffering from fatigue, have what is known as Preload Failure.

In this instance, Preload Failure is thought to come from an imbalance in the autonomic nervous system and results in reduced filling of the heart during exertion. The clinical trial will test the exercise response to Mestinon in people with ME / CFS, with Preload Failure.

Prior studies have shown improvement in patients in the general population with Preload Failure after treatment with Mestinon. Dr. Systrom intends to evaluate the short-term effects of Mestinon on the autonomic nervous system and neurovascular control in people with ME / CFS, who also have Preload Failure.

Studying these features will deepen our understanding of ME / CFS, and this trial may lead to new and specific therapeutic options for people with ME / CFS.”

This is just the first phase of this research. Much work remains to deliver treatments for ME / CFS and other chronic complex diseases. OMF strives to overcome the disparity in funding in our field of research, harnessing the passion of our community and the talent and commitment of researchers across the globe to bridge the funding gap and keep up research momentum towards a cure.

Will you please invest now in this essential research and become an OMF Sustaining Donor during #MayMomentum? Sustaining Donors have found the perfect way to invest in scientific research.

Your sustaining, monthly gift of any amount allows us to build momentum in the lab by insuring uninterrupted funding. Please consider investing today in the vital research conducted at our four, OMF funded Collaborative Research Centers.

Thank you, and stay safe,





Linda Tannenbaum
Open Medicine Foundation


It’s Giving Tuesday! Please give to #MayMomentum and show the world that fighting ME / CFS should matter to everybody!

Become a Sustaining Donor Now

Make a one-time donation for #MayMomentum today!

Please visit #MayMomentum for more information.

Prefer to use Facebook for monthly or onetime giving?
Check it out here: #MayMomentum Facebook

May 12th is ME / CFS International Awareness Day

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®


Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager